Brief: Eiger Biopharmaceuticals Announces Outlook And Planned 2022 Catalysts And Milestones
06/01/2022 13:51
Jan 6 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS ANNOUNCES OUTLOOK AND PLANNED
2022
CATALYSTS AND MILESTONES
* EIGER BIOPHARMACEUTICALS INC - PHASE 3 HDV D-LIVR
(LONAFARNIB)
STUDY TOPLINE DATA PLANNED BY END OF 2022
Source text for Eikon: ID:nPn1C87gla
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview